RxDoctor Payments Data

Haley Hughes, APRN

Allergy · Charleston, SCNPI 1063109247

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Sanofi at 25.4% of the total.

$2,984in general payments, 2019–2025

Across 113 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$757
  • AstraZeneca$646
  • Genentech USA, Inc.$325
  • Amgen$199
  • Regeneron Healthcare Solutions, Inc.$174
  • GSK$172
  • plus $712 from 14 others

What the payments were for

  • Food & beverage$2,87096%
  • Education$1144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$373,428
Medicare patients
232
Services billed
15,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab17$72,700
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,469
Spiriva RespimatTiotropium Bromide28$22,989
Breo ElliptaFluticasone/Vilanterol12$4,645
Wixela InhubFluticasone Propion/Salmeterol18$3,571
Epinephrine22$3,466
Albuterol Sulfate HfaAlbuterol Sulfate40$1,373
Azelastine Hcl29$691
Ipratropium Bromide17$676
Montelukast Sodium46$523
Fluticasone Propionate34$504
Prednisone14$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$172$38,11453 claims
Boehringer IngelheimSpiriva Respimat$15$22,98928 claims
Hikma Pharmaceuticals USAEpinephrine$104$3,46622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →